Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
Heritable TP53-related cancer risk syndrome : genotype-phenotype insights for prediction, prevention and personalization
PRODUCTS USED
ABSTRACT
Cancers can be classified as sporadic or hereditary. Approximately 10% are hereditary, caused by pathogenic germline variants, and are collectively referred to as hereditary cancer syndromes (HCS). Among these, the most severe is heritable TP53-related cancer risk syndrome (hTP53rc), also known as Li- Fraumeni syndrome (LFS), which is caused by germline TP53 variants. LFS is characterized by an exceptionally high lifetime cancer risk approaching 100% and is one of the most common genetic causes of childhood cancer. Affected individuals are predisposed to a wide spectrum of tumors. To enable early tumor detection, intensive surveillance starting at birth is recommended. However, limited understanding of TP53 genotype-phenotype correlations has resulted in uniform surveillance strategies irrespective of individual risk. Moreover, real- world adherence, germline testing behaviors, and the impact of false-positive findings in children remain poorly characterized.Therefore, we aimed to improve the clinical management and surveillance of patients with LFS by refining the understanding of genotype-phenotype relationships and assessing the clinical utility of surveillance.The principal findings of the papers comprising this thesis are outlined below: Paper I: We established the first nationwide germline TP53 registry in Sweden, comprising 176 carriers from 83 families, including all living and deceased individuals with LFS. The registry contains detailed genotype and phenotype data, including pedigree data. In total, 42 unique germline TP53 variants were identified, predominantly missense variants. When normalized to national population size, the registry demonstrated higher population coverage than previously published TP53 cohorts.This study highlights the Swedish germline TP53 registry as a national and international resource for clinical and research applications.Paper II: In the updated Swedish germline TP53 registry (189 carriers, 86 families), TP53 p.R181H was enriched (23% of all carriers), compared with international cohorts (